Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / OPTN - OptiNose: Potential Winner In Chronic Sinusitis Treatment

OPTN - OptiNose: Potential Winner In Chronic Sinusitis Treatment

OptiNose Inc.
  • OptiNose's revenue was $14.8 million in the first quarter, up 23.3% year-over-year.
  • The company has published the results of two Phase 3 clinical trials that met both primary and secondary endpoints.
  • Xhance may receive approval for chronic sinusitis in 2023, which would increase the potential number of patients by 10 million.

For further details see:

OptiNose: Potential Winner In Chronic Sinusitis Treatment
Stock Information
Company Name: OptiNose Inc.
Stock Symbol: OPTN
Market: NASDAQ
Website: optinose.com
Menu
OPTN OPTN Quote OPTN Short OPTN News OPTN Articles OPTN Message Board
Get OPTN Alerts

News, Short Squeeze, Breakout and More Instantly...